Literature DB >> 35870141

Melanoma in women of childbearing age and in pregnancy in California, 1994-2015: a population-based cohort study.

M Kiuru1,2, Q Li3, G Zhu1,4, J R Terrell1, K Beroukhim1, E Maverakis1, T H M Keegan3.   

Abstract

BACKGROUND: Melanoma is one of the most common malignancies during pregnancy. There is debate regarding the impact of pregnancy on the prognosis of melanoma. Recent large population-based studies from the United States are lacking.
OBJECTIVES: To determine the characteristics and survival of women with pregnancy-associated melanoma.
METHODS: This population-based, retrospective cohort study used California Cancer Registry data linked with state-wide hospitalization and ambulatory surgery data to identify 15-44-year-old female patients diagnosed with melanoma in 1994-2015, including pregnant patients. Multivariable logistic regression compared demographic and clinical characteristics between pregnant and non-pregnant women with melanoma. Multivariable cox proportional hazards regression models assessed melanoma-specific and overall survival.
RESULTS: We identified 13 108 patients, of which 1406 were pregnant. Pregnancy-associated melanoma was more frequent in Hispanic compared to non-Hispanic White women. Melanoma occurring post-partum was associated with greater tumour thickness (2.01-4.00 vs. 0.01-1.00 mm, odds ratio 1.75, 95% confidence interval: 1.03-2.98). There were otherwise no significant differences between pregnant and non-pregnant women. Worse survival was associated with Asian, Black and Native American race/ethnicity (vs. non-Hispanic White), lower neighbourhood socio-economic status, public insurance, tumour site, greater tumour thickness and lymph node involvement, but not pregnancy.
CONCLUSIONS: Melanoma occurring post-partum was associated with greater tumour thickness, but pregnancy status did not affect survival after melanoma. Race/ethnicity, socio-economic status and health insurance impacted survival, emphasizing the importance of reducing health disparities.
© 2022 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2022        PMID: 35870141      PMCID: PMC9560982          DOI: 10.1111/jdv.18458

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   9.228


  49 in total

1.  Cutaneous melanoma during pregnancy: is the controversy over?

Authors:  Marko Lens; Inger Rosdahl; Julia Newton-Bishop
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

2.  Does pregnancy influence melanoma prognosis? A meta-analysis.

Authors:  Athanassios Kyrgidis; Aimilios Lallas; Elvira Moscarella; Caterina Longo; Roberto Alfano; Giuseppe Argenziano
Journal:  Melanoma Res       Date:  2017-08       Impact factor: 3.599

3.  Pregnancy-associated melanoma (PAMM): Is there truly a worse prognosis? Would not sound alarm bells just yet….

Authors:  Kathryn J Martires; Miriam Keltz Pomeranz; Jennifer A Stein; Jane M Grant-Kels; Marcia S Driscoll
Journal:  J Am Acad Dermatol       Date:  2016-08       Impact factor: 11.527

4.  Predictors of neighborhood risk for late-stage melanoma: addressing disparities through spatial analysis and area-based measures.

Authors:  Shasa Hu; Recinda Sherman; Kristopher Arheart; Robert S Kirsner
Journal:  J Invest Dermatol       Date:  2013-11-07       Impact factor: 8.551

5.  Lack of effect of pregnancy on outcome of melanoma. For The World Health Organisation Melanoma Programme.

Authors:  R M MacKie; R Bufalino; A Morabito; C Sutherland; N Cascinelli
Journal:  Lancet       Date:  1991-03-16       Impact factor: 79.321

6.  Racial and Socioeconomic Disparities in the Delivery of Immunotherapy for Metastatic Melanoma in the United States.

Authors:  Waqar Haque; Vivek Verma; Edward Brian Butler; Bin S Teh
Journal:  J Immunother       Date:  2019 Jul/Aug       Impact factor: 4.456

7.  Association between melanoma thickness, clinical skin examination and socioeconomic status: results of a large population-based study.

Authors:  Philippa H Youl; Peter D Baade; Sanjoti Parekh; Dallas English; Mark Elwood; Joanne F Aitken
Journal:  Int J Cancer       Date:  2011-05-01       Impact factor: 7.396

8.  Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment.

Authors:  Jason A Zell; Pelin Cinar; Mehrdad Mobasher; Argyrios Ziogas; Frank L Meyskens; Hoda Anton-Culver
Journal:  J Clin Oncol       Date:  2008-01-01       Impact factor: 44.544

9.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Authors:  Jeffrey Weber; Mario Mandala; Michele Del Vecchio; Helen J Gogas; Ana M Arance; C Lance Cowey; Stéphane Dalle; Michael Schenker; Vanna Chiarion-Sileni; Ivan Marquez-Rodas; Jean-Jacques Grob; Marcus O Butler; Mark R Middleton; Michele Maio; Victoria Atkinson; Paola Queirolo; Rene Gonzalez; Ragini R Kudchadkar; Michael Smylie; Nicolas Meyer; Laurent Mortier; Michael B Atkins; Georgina V Long; Shailender Bhatia; Celeste Lebbé; Piotr Rutkowski; Kenji Yokota; Naoya Yamazaki; Tae M Kim; Veerle de Pril; Javier Sabater; Anila Qureshi; James Larkin; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2017-09-10       Impact factor: 91.245

10.  Incidence and outcomes of pregnancy-associated cancer in Australia, 1994-2008: a population-based linkage study.

Authors:  Y Y Lee; C L Roberts; T Dobbins; E Stavrou; K Black; J Morris; J Young
Journal:  BJOG       Date:  2012-09-05       Impact factor: 6.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.